The diabetes epidemic in the US continues unabated hand in hand with the concurrent epidemics of obesity and physical inactivity. At present, there are about 34 million US adults living with type 2 diabetes (10.2% of the US adult population). Another 88 million US adults have abnormal glucose levels that fall short of a diabetes diagnosis (an additional 34.5% of the adult US population). 1,2 These numbers reflect the fact that nearly 75% of US adults have a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) in the overweight or obese range, 3 and 45% engage in no moderate-or vigorous-intensity physical activity in a typical week. 4 Despite convincing evidence supporting guidelines for lifestyle change and medical therapy, progress in the control of diabetes-related risk factors (ie, hypertension, dyslipidemia, hyperglycemia) has plateaued 5,6 or, in some cases, may have worsened. 7 As a result, millions of individuals remain at risk for the microvascular and macrovascular complications of diabetes, disability, and early mortality. The gaps in receipt of recommended care are greater for younger adults (aged 18-44 years) and members of at-risk racial and ethnic groups (American Indian/Alaska Native, Asian American, Black, Hispanic/Latinx, and Native Hawaiian/ Pacific Islander adults) than for other adults. 8 In its 2021 recommendation statement, 9 the United States Preventive Services Task Force (USPSTF) has lowered the starting age of screening for prediabetes and type 2 diabetes from 40 to 35 years for adults with overweight or obesity, while maintaining the upper age of screening at 70 years (B recommendation). The USPSTF recommends that clinicians offer or refer patients with abnormal blood glucose levels to intensive behavioral counseling interventions to promote a healthful diet and physical activity. To date, however, no high-quality clinical studies have directly shown clinical benefit from screening adults starting at age 35 years for abnormal glucose metabolism. This recommendation is therefore driven by an updated evidence report and systematic review 10 that demonstrates that screening does little direct harm, that individuals can prevent progression to diabetes with intensive lifestyle changes, and that interventions for newly diagnosed diabetes have a moderate benefit in reducing all-cause mortality, diabetes-related mortality, and risk of myocardial infarction after 10 to 20 years of intervention. Indeed, longterm follow-up of the UK Prospective Diabetes Study from the 1980s of tighter glycemic control (for that era, hemoglobin A 1c <7%) suggested that earlier rather than later glycemic control Opinion Editorial
E2JAMA